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A B S T R A C T
Background: Patient engagement is vital in multiple sclerosis (MS) in order to optimise outcomes for patients,
society and healthcare systems. It is essential to involve all stakeholders in potential solutions, working in a
multidisciplinary way to ensure that people with MS (PwMS) are included in shared decision-making and disease
management. To start this process, a collaborative, open environment between PwMS and healthcare profes-
sionals (HCPs) is required so that similarities and disparities in the perception of key areas in patient care and
unmet needs can be identiﬁed. With this patient-centred approach in mind, in 2016 the MS in the 21st Century
Steering Group formed a unique collaboration to include PwMS in the Steering Group to provide a platform for
the patient voice.
Methods: The MS in the 21st Century initiative set out to foster engagement through a series of open-forum joint
workshops. The aims of these workshops were: to identify similarities and disparities in the perception and
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prioritisation in three key areas (unmet needs, the treatment burden in MS, and factors that impact patient
engagement), and to provide practical advice on how the gaps in perception and understanding in these key
areas could be bridged.
Results: Combined practical advice and direction are provided here as eight actions: 1. Improve communication
to raise the quality of HCP–patient interaction and optimise the limited time available for consultations. 2.
Heighten the awareness of ‘hidden’ disease symptoms and how these can be managed. 3. Improve the dialogue
surrounding the beneﬁt versus risk issues of therapies to help patients become fully informed and active par-
ticipants in their healthcare decisions. 4. Provide accurate, lucid information in an easily accessible format from
reliable sources. 5. Encourage HCPs and multidisciplinary teams to acquire and share new knowledge and in-
formation among their teams and with PwMS. 6. Foster greater understanding and awareness of challenges faced
by PwMS and HCPs in treating MS. 7. Collaborate to develop local education, communication and patient-
engagement initiatives. 8. Motivate PwMS to become advocates for self-management in MS care.
Conclusion: Our study of PwMS and HCPs in the MS in the 21st Century initiative has highlighted eight practical
actions. These actions identify how diﬀerences and gaps in unmet needs, treatment burden, and patient en-
gagement between PwMS and HCPs can be bridged to improve MS disease management. Of particular interest
now are patient-centred educational resources that can be used during time-limited consultations to enhance
understanding of disease and improve communication. Actively bridging these gaps in a joint approach enables
PwMS to take part in shared decision-making; with improved communication and reliable information, patients
can make informed decisions with their HCPs, as part of their own personalised disease management.
1. Introduction
The Multiple Sclerosis in the 21st Century initiative, established in
2011 and led by a Steering Group of international experts involved in
the care and management of people with multiple sclerosis (PwMS), is
committed to improving the standard of care for PwMS internationally
(Box 1). In its 2012 consensus statement, the Steering Group identiﬁed
the need for a better understanding of the unmet needs of PwMS and
healthcare professionals (HCPs) in an eﬀort to optimise disease man-
agement and improve patient outcomes (Rieckmann et al., 2013). One
of the strategies put forward to achieve this goal, was to seek to un-
derstand and overcome the barriers of patient engagement in multiple
sclerosis (MS) (Rieckmann et al., 2015).
It is essential to involve all stakeholders in potential solutions,
working in a multidisciplinary way to ensure that PwMS can participate
appropriately in their care (Rieckmann et al., 2015). Critically, adding
the perspective of patients to that of their HCPs is essential for opti-
mising care (Golla et al., 2012). While a shared decision-making ap-
proach in patient-centred care has been the focus of recent publications
in MS (Ballesteros et al., 2017; Col et al., 2017; Colligan et al., 2017), it
is still not as well developed as it is in other therapeutic areas, such as in
the community of people living with human immunodeﬁciency virus
(HIV)/acquired immunodeﬁciency syndrome (AIDS).
The achievements of people living with HIV/AIDs were held in high
regard by both the HCPs and PwMS in the collaborative group. These
achievements included persuading governments and societies to change
their approach to the AIDS epidemic, helping negotiate reductions in
treatment costs with pharmaceutical companies, inﬂuencing how
people with HIV were treated, and, through education, helping to re-
verse the stigma associated with the disease.
People living with HIV/AIDS also developed the Denver Principles
(Anon, 1983), which called for a new relationship between people with
AIDS, their healthcare providers, and society. They demanded that
physicians perceive their patients as ‘whole people’, who should receive
‘accurate information’. Patient engagement and action has not only had
an impact on the way HIV is managed today, but was also instrumental
in driving local, domestic and international public health policy-making
(Wright, 2013). These principles stated that equal weight should be
given to patients’ and HCPs’ opinions regarding care; this revolutionary
viewpoint continues to inﬂuence today’s healthcare approaches.
In line with the early views of HIV/AIDS patients and advocates,
both PwMS and HCPs believe that collaborative interactions are re-
quired to fully understand and address the complex issues involved in
MS, and to improve future care; a collective patient–HCP voice is a
positive and powerful one. Although a patient-centred approach in MS
has started to emerge in the literature (Ballesteros et al., 2017; Col
et al., 2017; Colligan et al., 2017) there is still a lack of recognition of
the importance of a shared PwMS–HCP perspective in MS care (Tintoré
et al., 2016).
With this patient-centred approach in mind, in 2016 the MS in the
21st Century Steering Group formed a unique collaboration to include
PwMS in the group. Using a series of open-forum workshops attended
by this newly formed joint Steering Group, the participants set out to
foster collaboration and explore diﬀerences in the way HCPs and PwMS
Box 1
The MS in the 21st Century initiative.
Members of the Steering Group include: 14 HCPs (including neurologists, a neuropsychologist, a health economist, an MS nurse, an MS
rehabilitation specialist, and patient advocacy group representatives) and 11 PwMS.
The group meets regularly to discuss the creation of programmes and awareness to achieve the following objectives:
• to improve communication between patients and HCPs through joint education and interaction
• to improve awareness of and access to treatment and care through: specialists (neurologists), other HCPs and the wider healthcare team, and
specialist services (including physiotherapy, rehabilitation and counselling)
• to improve provision/access to information by: providing high-quality information from credible sources, increasing public awareness of MS,
and focusing on e-medicine and e-education
• to promote patient activation and self-management by: highlighting the signiﬁcance and beneﬁts of self-management, empowering patients
through education and communication, and improving the social well-being and integration of MS patients.
Abbreviations: HCPs, healthcare professionals; MS, multiple sclerosis; PwMS, people with MS.
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deﬁne and prioritise areas of greatest unmet need in MS. The topics
discussed in the workshops included: unmet needs in disease manage-
ment, the treatment burden in MS, and factors that impact on successful
patient engagement. The group proposed that if diﬀerences exist in the
perception and prioritisation of these issues, then shared decision-
making, and ultimately true patient-centred care, will be diﬃcult to
achieve.
2. Methods
In 2016, 11 PwMS were invited to join the MS in the 21st Century
Steering Group. Participants were chosen to include a mix of gender
and age at varying stages of disease: newly-diagnosed MS, primary
progressive MS (PPMS), and relapsing remitting MS (RRMS), and were
drawn from diﬀerent European countries and the USA. These PwMS
agreed to take part in discussions, and be involved in the identiﬁcation
of practical advice for the future.
During a joint meeting with the HCPs in March 2016, the PwMS and
HCPs participated in separate but concurrent workshops to discuss their
perception of unmet needs, the treatment burden in MS, and factors
that aﬀect patient engagement. The aim of these parallel workshops
was for each group to identify the key issues from their perspective (i.e.
that of either HCP or patient) for each of the three discussion topics.
The groups were asked to prioritise their results for each of the three
topics in terms of the perceived importance to the improvement of care
and patient outcomes. The results of the parallel workshops were
shared and reviewed by both groups.
A subsequent joint workshop, attended by both groups, was de-
signed to share ﬁndings, and discuss disparities and similarities in the
results. All workshops, chaired by members of the MS in the 21st
Century initiative and facilitated by professional moderators, were de-
signed as open-forum workshops to encourage candid discussion among
all participants.
A ﬁnal workshop was held in September 2016 to discuss and con-
ﬁrm actions based on the issues identiﬁed in the previous workshops.
This workshop was comprised of the same members who had taken part
in the previous workshops (11 PwMS and 10 HCPs), attending either in
person or via teleconference. From the results of these discussions, the
joint group outlined practical advice and direction for how diﬀerences
and gaps could be bridged by the wider MS community.
3. Results
Key outcomes from the workshops to identify disparities in per-
ceptions and priorities of unmet needs, treatment burden, and patient
engagement between the PwMS and HCP groups are presented below.
Practical advice and direction from this initial collaboration is covered
in Section 4.
3.1. Topic 1: unmet needs in disease management
The similarities and disparities between the HCP and PwMS groups
in the perception and prioritisation of key unmet needs in MS are
presented in Table 1.
Five main areas were identiﬁed within this topic: symptom man-
agement, access to treatment and reimbursement, personalised care,
education and communication, and resources and information. Both
groups identiﬁed ‘a cure for MS’ as the single greatest unmet need.
One particular unmet need for PwMS was the diﬃculty in com-
municating the invisible/‘hidden’ symptoms of MS that are hard to
detect and monitor during standard neurological consultations.
Although HCPs acknowledged the impact of these hidden symptoms,
they considered symptomatic treatment and disease progression to be
more signiﬁcant than hidden symptoms. PwMS also considered that
their changing practical needs relating to disease disability and quality
of life (QoL), such as social care and employment issues, were not
consistently being met; these particular aspects of care were not iden-
tiﬁed by HCPs as a high priority.
HCPs identiﬁed the inability to oﬀer speciﬁc therapies due to local
treatment policies and high costs as an unmet need, and this was mir-
rored by the identiﬁcation by the PwMS of a ‘reluctance’ on the part of
HCPs to prescribe particular therapies. PwMS reported disparities in
reimbursement policies in diﬀerent countries, resulting in a barrier to
personalised therapy. Time constraints was another issue raised by
HCPs and PwMS; both groups were dissatisﬁed with the limited time
available for clinical consultations, and acknowledged that this im-
pacted on the ability of HCPs to discuss the disease and treatment op-
tions with patients. Both groups acknowledged the need for additional
research into the impact of current therapies on QoL outcomes for
PwMS, and the need to raise public awareness and understanding of MS
to reduce prejudice and discrimination.
3.2. Topic 2: burden of treatment in MS
Similarities and disparities between the HCP and PwMS groups in
the perception and prioritisation of key factors aﬀecting the treatment
burden in MS are presented in Table 2. Three main areas were identi-
ﬁed within this topic: risk versus beneﬁt of MS therapies; treatment
decisions; and compliance, adherence and monitoring.
From a PwMS perspective, it appeared that HCPs focus on the ne-
gative aspects of treatment (risk and potential adverse eﬀects), rather
than on the positive aspects (impact on disease progression, eﬀect on
symptoms). Conversely, HCPs reported apprehension over the level of
risk patients were willing to consent to in relation to their therapy.
Although anxiety about side eﬀects with respect to therapy escalation
was a shared concern for both HCPs and PwMS, this translated into
hesitancy on the part of HCPs to escalate treatment. Both groups ac-
knowledged that adherence to treatment was an issue, but for diﬀerent
reasons: for PwMS, the complexity of treatment added to the adherence
burden; whereas for HCPs, patient adherence issues were due to the
side eﬀects of treatment.
HCPs identiﬁed the issue of PwMS not engaging in, or taking re-
sponsibility for, their disease management. Both groups believed that a
mutually respectful, shared decision-making approach was necessary to
enable both HCPs and PwMS to take responsibility for disease man-
agement.
3.3. Topic 3: patient engagement
The perception and prioritisation of key factors aﬀecting patient
engagement in MS are presented as a joint perspective agreed by both
the HCPs and PwMS. HCPs and PwMS believed that the adoption by
HCPs of a holistic approach during consultations was critical to patient
engagement, and had a direct inﬂuence on how patients engaged with
their HCPs. The three principal factors that were considered to have the
most positive impact on patient engagement were: technology (elec-
tronic healthcare, electronic tools and resources); education (informed
and supportive HCPs, access to information, patient-driven informa-
tion); and support and involvement within society (peer support and
social activities). For those in the PwMS group who had signiﬁcant
mobility issues that made engaging in society diﬃcult, technology and
the internet enabled peer support, reducing feelings of isolation.
HCPs and PwMS thought that factors that negatively aﬀected pa-
tient engagement included lack of time with HCPs, the public image of
MS (including misconceptions about MS), and a lack of access to high-
quality information (lack of reliable resources, information that is out
of date) (Reen et al., 2017a,).
The negative impact of MS stereotypes on daily living was high-
lighted by newly-diagnosed patients in the PwMS group, for whom an
overwhelming amount of inappropriate and inaccurate information
aﬀected their motivation towards patient engagement. A particular
issue raised by HCPs and PwMS was that employment and staying part
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Table 1
Similarities and disparities between HCPs and PwMS in the perception and prioritisation of key unmet needs in MS.
HCPs PwMS Similarities and disparities
Symptom management
• A cure for MS• Symptomatic treatment and disease progression• A lack of treatments available to manage progressive
MS and the symptomatic aspects of the disease
• A cure for MS• A lack of advances in the recognition and treatment of
MS disease progression
• Invisible/‘hidden’ symptoms and mental health
aspects of MS were diﬃcult for PwMS to
communicate, as well as being diﬃcult to monitor and
detect during neurological consultations
• Currently available therapies and approaches were not
being used to address invisible/‘hidden’ symptoms due
to a lack of recognition by HCPs
• Practical needs, not just clinical symptoms, relating to
disease disability and QoL were not being met
• Similarities:
o both HCPs and PwMS recognised the need for a cure
for MS and a lack of treatments/advances to manage
disease progression
• Disparities:
o PwMS placed a greater emphasis than HCPs on
hidden symptoms, the mental health aspects of MS,
and management of these symptoms
o HCPs considered symptomatic treatment to be more
important than hidden symptoms
o The practical needs of PwMS were important to
patients but were not identiﬁed as a pressing
requirement by HCPs
Access to treatment and reimbursement
• Access to appropriate care is critical; inability to oﬀer
speciﬁc therapies due to local treatment stipulations/
high treatment costs hinders care
• Need for more research into the impact of current
therapies on QoL outcomes
• Perception that PwMS prefer not to discuss risks of
treatment
• Lack of, or delay in, reimbursement for MS
treatments, can slow the uptake of innovations
• Time spent counselling and providing information is
often not reimbursed
• Lack of access to treatment and treatment support• Reluctance on the part of some HCPs to prescribe
particular therapies
• Lack of awareness of speciﬁc therapies/latest
therapeutic options among some HCPs
• Need for more research into the impact of current
therapies on QoL outcomes
• HCPs tend to spend too much time focusing on the
risks of treatment, whereas PwMS want to discuss both
risks and beneﬁts
• More stakeholders need to be educated about the
burden of MS to individuals so that they have a better
understanding of the impact of reimbursement
constraints
• Similarities:
o Both HCPs and PwMS acknowledged that access to
appropriate treatment/care is important
o Both groups recognised the need for more research
into the impact of current therapies on QoL outcomes
• Disparities:
o PwMS believed there was a lack of awareness of
speciﬁc therapies/reluctance to prescribe certain
therapies among HCPs; in turn, some HCPs were
frustrated by not being able to oﬀer speciﬁc therapies
due to local restrictions
o PwMS maintain that HCPs spend more time focusing
on the risks of treatment
o HCPs were focused on cost issues, reimbursement
(including activities that were not reimbursed), and
the complexity of this system
o PwMS were focused on the impact that
reimbursement constraints actually had on their day-
to-day living
o HCPs believe that PwMS did not want to discuss the
risks of treatment
o PwMS did want to discuss the risks of treatment to
some extent, but preferred to discuss the beneﬁts of
treatment
Personalised care
• Professional training needs to oﬀer more information
on the provision of personalised and holistic care
• Time to communicate with PwMS and the
multidisciplinary teams about the best and most
appropriate options for each individual is limited
• Attention to personalised care needs greater time and
resources in many healthcare systems
• Acknowledgement that no two PwMS have the same
experience of the disease
• Dissatisfaction with the limited time available for
clinical consultations
• Speciﬁc priorities are not consistently addressed
• Similarities:
o Both groups acknowledged that investment in
resources is needed to fully achieve personalised care
o Both HCPs and PwMS thought that the lack of time
available during patient and HCP communication/
clinical consultations was insuﬃcient
• Disparities:
o HCPs also believed that lack of time was an issue for
multidisciplinary teams trying to determine the best
options for the management of individual patients
o PwMS considered that their priorities were not
necessarily addressed during consultations; this point
was not mentioned by HCPs
Education and communication
• Professional education and understanding of the
needs of PwMS requires improvement
• Improved communication with PwMS regarding
complex disease issues such as progression is
important
• A lack of public awareness should be addressed
through education and communication to dispel
misconceptions about MS and reduce prejudice and
discrimination in the workplace
• The HCP–PwMS relationship was deemed central to
achieving optimal care
• Greater education for HCPs about hidden symptoms
would help them to see the ‘whole patient’; this
education should begin during the early part of
training to reinforce the need to treat patients
holistically
• HCPs do not fully understand what is most important
to PwMS
• PwMS expressed the view that the lack of public
awareness should be addressed through education and
communication to dispel misconceptions about MS
and reduce prejudice and discrimination in the
workplace
• Similarities:
o PwMS recognised the importance of the HCP–PwMS
relationship, and HCPs acknowledged that more can
be done to improve the communication of complex
issues to PwMS
o Both groups highlighted the lack of public
awareness, misconceptions and prejudice
surrounding MS
o Both HCPs and PwMS recognised that more can be
done to improve the understanding of and education
about MS and PwMS
• Disparities:
o PwMS generally thought that HCPs did not
understand what is important to them (i.e. HCPs
adopted a ‘one size ﬁts all’ approach)
o PwMS speciﬁcally mentioned the need to educate
HCPs about hidden symptoms and holistic treatment
Resources and information
• Information for patients needs to come from vetted
and reliable sources
• PwMS have individual information needs • Similarities:
(continued on next page)
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of society was not covered in a typical consultation. Both HCPs and
PwMS expressed the view that the lack of patient support in this area
had the potential for patients to become socially isolated. HCPs and
PwMS considered that the lack of overall support – including social,
employment, family and legal support – had a negative impact on pa-
tient engagement.
4. Discussion
A number of key outcomes were highlighted in the workshops
identifying disparities in the perception and prioritisation of unmet
needs, treatment burden, and patient engagement. The diﬀerences, and
the underlying reasons for them, need to be addressed before HCPs and
PwMS can truly engage in the shared decision-making process. Both
groups need to place equal importance on certain key outcomes to
enable the process of patient engagement and shared decision-making
that will ultimately lead to patient satisfaction and best patient care.
PwMS need to be receptive to ‘highest priority’ issues from the HCP
perspective, and HCPs need to consider how an acknowledgement of
PwMS-speciﬁc and individual concerns will enhance communication.
Although advances in medicine, technology and healthcare services
oﬀer improved clinical outcomes and QoL, there is also an increasing
reliance on patients’ skills and motivation to optimise all the outcome
beneﬁts available. The consequences of patients not engaging with their
own healthcare are, not surprisingly, borne most heavily by the patients
themselves and their families, and include emotional, physical, social
and ﬁnancial implications (Rieckmann et al., 2015). Patients have
better health outcomes when involved in their own healthcare; moti-
vated patients show improved treatment adherence, reduced risk fac-
tors and improved health outcomes (Rieckmann et al., 2015; Tintoré
et al., 2016). A shared decision-making approach between HCPs and
PwMS is essential for patient-centred care.
From the key outcomes, HCPs and PwMS reached agreement on
combined practical advice, which is presented in Section 4.1 as eight
practical actions. These opinions and actions were elicited from a re-
presentative but limited number of HCPs and PwMS. A current focus for
the Steering Group is to validate these ﬁndings with a larger and
broader group of HCPs and PwMS.
Table 1 (continued)
HCPs PwMS Similarities and disparities
• The complexity of claims and the time and resources
needed to process reimbursement hinders treatment
options
• Educational resources often lack disease information,
with little or no consideration of speciﬁc disease states
• Lack of resources limits access to treatments and
supporting services
o Both groups acknowledged the need for better
quality resources and information
• Disparities:
o PwMS expressed the need for more personalised
information and resources speciﬁc to diﬀerent stages
of the disease
Abbreviations: HCPs, healthcare professionals; MS, multiple sclerosis; PwMS, people with MS; QoL, quality of life.
Table 2
Similarities and disparities between HCPs and PwMS in the perception and prioritisation of key factors aﬀecting treatment burden in MS.
HCPs PwMS Similarities and disparities
Risk versus beneﬁt of MS therapies
• Level of risk of MS therapies that patients were willing
to accept was a cause for concern among HCPs
• More patient support was needed to understand the
concept of risk and to accept the nature of the risk posed
by diﬀerent therapies
• HCP and patient anxiety about treatment side eﬀects
may result in a reluctance to escalate treatment –
possibly due to responsibility and liability concerns
• HCPs focus more on the risk than the
beneﬁt of treatments
• More information on the beneﬁts of new
treatments rather than focusing on risks
• Patient anxiety related to side eﬀects
results in neurologist hesitancy to escalate
treatment
• Similarities:
o Both HCPs and PwMS expressed anxiety about side eﬀects
with respect to therapy escalation
• Disparities:
o HCPs believed that PwMS did not appreciate the concept of
risk, and possibly the side eﬀects of treatment
o PwMS considered that HCPs focused on the negative aspects
of treatment (risk and potential adverse eﬀects) rather than
on the beneﬁts of new treatments
Treatment decisions
• Lack of time and general access to the medical team is a
treatment limitation
• A lack of access to disease-modifying treatments• Irregular review monitoring with long waiting times• Geography-related inequality in treatment options• Need for novel treatments
• Concern about the practical implications of
treatment and eﬀects on QoL
• Some treatments carry a high ﬁnancial
burden
• Lack of reimbursement can lead to delays
in treatment and risks inappropriate or
suboptimal treatment
• Need for new and novel treatments
• Similarities:
o Novel treatment choices were welcomed by both HCPs and
PwMS
• Disparities:• HCPs were concerned with the barriers to eﬀective treatment
choice: limited time spent with patients, long waiting times,
lack of access to medical teams and certain treatments
• PwMS placed emphasis on the practical implications of
treatment and how it aﬀected their QoL.
Compliance, adherence and monitoring
• Need for frequent and extensive disease and treatment
monitoring can aﬀect compliance
• Side eﬀects of treatment were important for both
initiation and adherence; irregular monitoring or long
waiting times caused suboptimal side-eﬀect monitoring
• The complexity of treatment adds to the
adherence burden
• HCPs provide an inadequate explanation of
the treatment options
• Treatment achievements or successes were
often overlooked
• Side-eﬀect management needs to be better
supported
• Similarities:
o Both groups acknowledged adherence to treatment was an
issue
• Disparities:
o PwMS thought that side-eﬀect management was often poorly
supported; but HCPs were aware of this and cited that
irregular monitoring/suboptimal monitoring could contribute
to this
o PwMS placed importance on treatment options being
explained and treatment achievements being acknowledged;
these points were not mentioned by HCPs
Abbreviations: HCPs, healthcare professionals; MS, multiple sclerosis; PwMS, people with MS; QoL, quality of life.
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4.1. Practical advice and direction for action
4.1.1. Improve communication to raise the quality of HCP–patient
interaction and optimise the limited time available for consultations
Enhanced communication with HCPs that includes appropriately
pitched information, together with honesty and respect from both
groups, was considered vital to optimising patient outcomes. There is a
growing recognition of the value of eﬀective communication and con-
ﬂict-management skills (Ha and Longnecker, 2010), which is high-
lighted by the inclusion of communication-skills training as part of
medical education in Europe and the USA (Hausberg et al., 2012). Due
to limited time and resources, it is imperative that HCP–PwMS con-
sultations and health service interactions are maximised through high-
quality communication. In chronic diseases, improved HCP–patient
communication has been associated with better treatment adherence,
satisfaction, understanding and retention of information, and overall
health outcomes (Kinsman et al., 2010; Reen et al., 2017b; Langdon
et al., 2012).
4.1.2. Heighten the awareness of ‘hidden’ disease symptoms and how these
can be managed
Symptom-free disease should be the current goal of treatment, al-
though it was evident from the results that a greater appreciation of the
impact of invisible/‘hidden’ symptoms is required in order to have a
positive impact on the QoL of PwMS. Hard-to-measure outcomes or
‘hidden’ symptoms continue to receive little attention in disease man-
agement, and this is corroborated in the literature (Le Fort et al., 2011;
Mehr and Zimmerman, 2015). Hidden symptoms of fatigue, depression,
cognition, sleep problems, sexual problems (Colombo et al., 2014;
Learmonth et al., 2016; Marrie et al., 2017; Solari, 2014), and the
mental and emotional impact of MS (Vickrey et al., 1999) continue to
be unmet needs. An increased awareness of the impact of hidden
symptoms, as well as of the mental health aspects, of MS could help to
elicit positive change in addressing the unmet needs of PwMS.
4.1.3. Improve the dialogue surrounding the beneﬁt versus risk issues of
therapies to help patients become fully informed and active participants in
their healthcare decisions
As the therapeutic landscape of MS evolves, a thorough evaluation
of the potential risks and beneﬁts of treatments is critical to decision-
making. However, current evidence suggests that other factors should
also be taken into account, including the natural history of untreated
disease, monitoring capabilities, co-morbid illnesses, co-medications,
patient preferences, attitudes, ability to adhere to medication, and pa-
tient expectations (Lugaresi et al., 2013; Saposnik et al., 2016).
The beneﬁt versus risk proﬁle of any treatment strategy is a time-
consuming and complicated task, and depends on the risk-taking ten-
dencies of patients and their HCPs. A lower level of safety concern
about disease-modifying drugs among PwMS compared with HCPs was
highlighted in a recent focus-group study (Kremer et al., 2017). A
greater depth of information on treatment risk/beneﬁt has the potential
to improve patient engagement and adherence, and reduce the per-
ceived treatment burden (Lizán et al., 2014). It has been suggested that,
in the event of HCPs and PwMS disagreeing about acceptable risk,
PwMS may be willing to accept greater levels of risk in exchange for
therapeutic beneﬁt, e.g. if treatment allows them to continue to walk
(Reed Johnson et al., 2009). A lack of information regarding risks and
desired outcomes may also increase the stress of treatment decisions for
the patient (Barre et al., 2015).
4.1.4. Provide accurate, lucid information in an easily accessible format
from reliable sources
The Steering Group’s aspiration is for all PwMS to have access to
accurate, up-to-date, reliable and comprehensible information that will
help empower them and allow them to feel better placed to make
treatment decisions. Educational resources should also be speciﬁc,
disease-stage information, user-friendly, and in an accessible format for
PwMS, their families and carers. Inappropriate, inaccurate or over-
whelming information negatively aﬀects the motivation of PwMS,
preventing full engagement with their disease, treatment and health-
care needs. Studies suggest that PwMS frequently report diﬃculties in
locating personally relevant information on the internet. The higher
educational level required to understand health information worsens
health inequalities, preventing full participation in decision-making
(Moccia et al., 2016).
4.1.5. Encourage HCP and multidisciplinary teams to acquire and share
new knowledge and information among their teams and with PwMS
Recent advances in the ﬁeld of MS, largely driven by progress in
diagnosis, MS neurobiology, and the development of new treatments,
have been identiﬁed (Mehr and Zimmerman, 2015). However, such
advances can add to the disease and treatment burden experienced by
PwMS and HCPs. Rapid advances in treatment options may lead to
frustration when HCPs are unaware of the latest data, or do not have
the capacity to communicate relevant information to patients. The
growing ﬁnancial constraints placed on healthcare services, and the
lack of reimbursement in some healthcare systems, adds to this burden
by limiting the time available for, or the number of, consultations.
A lack of resources was deemed to be a negative inﬂuence on the
HCP–PwMS relationship, reducing the quality of interaction. This ob-
servation aligns with similar ﬁndings by others that highlight the im-
portance of adequate consultation time and access to the general
medical team in addressing disease and treatment burden (Le Fort et al.,
2011).
4.1.6. Foster greater understanding and awareness of the challenges faced
by PwMS and HCPs in treating MS
Communication and education were considered essential for raising
awareness and understanding of MS and dispelling misconceptions
about the disease. Misconceptions about MS can hinder acceptance of
the diagnosis in new PwMS (Fallahi-Khoshknab et al., 2014) and can
cause health anxiety in all PwMS, with a subsequent impact on QoL,
perception of symptoms (Hayter et al., 2016), and an increased risk of
depression (Santoro et al., 2016). Conversely, positive personal per-
ceptions about MS, such as a perception of treatment control or a rea-
listic MS timeline perspective, are more strongly correlated with disease
self-management than are objective clinical variables such as the se-
verity, type and duration of MS (Wilski and Tasiemski, 2016).
Education and an increased awareness of MS among the general
public may help PwMS to feel less excluded from society, as well as
potentially lead to better healthcare and, ultimately, positively inﬂu-
ence reimbursement/funding decisions in healthcare systems.
Some of the basic needs of PwMS that were identiﬁed as unfulﬁlled
almost two decades ago, such as a holistic approach to care, continue to
remain unmet today (Colombo et al., 2014; Learmonth et al., 2016;
Solari, 2014). The ongoing reductions in healthcare budgets further
preclude the provision of the personalised care that is critical to PwMS.
Adopting a shared approach that considers the views of both PwMS and
HCPs can be more eﬀective in achieving better outcomes in MS care by
fostering a truly co-operative and holistic understanding of the issues
faced by PwMS.
4.1.7. Collaborate to develop ‘joint’ local education, communication and
patient-engagement initiatives
Although there are many examples of educational and awareness
activities designed and delivered for and by HCPs and PwMS as sepa-
rate entities, there are few opportunities for the groups to interact, learn
and communicate together outside the clinical setting. Such opportu-
nities should be encouraged to foster better understanding and colla-
boration between the groups. A co-alliance of PwMS and HCPs enables
the alignment of objectives, recognises the range of diﬀerent patient
needs, and solicits an inclusive view for the best way to resolve these
P. Rieckmann et al. Multiple Sclerosis and Related Disorders 19 (2018) 153–160
158
issues. Without collaboration, there is a risk that HCPs and PwMS will
work at cross-purposes, and that resolution of issues will, at best, be
delayed.
Involvement in society and engagement with community activities
were considered key factors in promoting inclusion and motivating
patients to further engage in their healthcare needs. The engagement of
patients in their own healthcare has been described as the ‘blockbuster
drug of the century’ (Rieckmann et al., 2015). From the early stages of
this disease, PwMS are vulnerable to social exclusion; negative per-
ceptions of the disease can also invoke prejudices and inequalities, and
have a negative impact on employment opportunities (Oreja-Guevara
et al., 2017). As disability worsens, the ability to work and interact
socially becomes further restricted, meaning that eﬀorts to enhance
collaboration and develop a globalised MS community are therefore
much needed.
4.1.8. Motivate PwMS to become advocates for self-management in MS care
The responsibility for PwMS to engage in their own health lies with
everyone involved in their care as well as with the patients themselves.
Harnessing this sense of responsibility towards self-management, at all
levels, may be instrumental in motivating engagement (Rieckmann
et al., 2015). A sense of responsibility may also be fostered by PwMS
becoming patient-educators for other patients or medical professionals.
This has been shown to be a rewarding and therapeutic experience,
oﬀering patients beneﬁts such as raising their self-esteem and sense of
empowerment, gaining new insights into their own issues, fostering a
better understanding of the patient–doctor relationship and improving
QoL (Rieckmann et al., 2015).
5. Conclusion
Our study of PwMS and HCPs in the MS in the 21st Century in-
itiative has highlighted eight practical actions for the wider MS com-
munity. These actions identify how diﬀerences and gaps in unmet
needs, treatment burden, and patient engagement between PwMS and
HCPs can be bridged by improving MS disease management. Shared
decision-making enables patients to make informed decisions with their
HCPs as part of their own personalised disease management. Of parti-
cular interest now is the development of patient-centred educational
resources that can be used during consultations to enhance disease
understanding and improve communication between PwMS and their
HCPs. This patient-centred approach not only allows patients to be
more comfortable with the decisions they make, but enables active
participation in self-care.
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